ZNF410 represses fetal globin by singular control of CHD4

被引:0
作者
Divya S. Vinjamur
Qiuming Yao
Mitchel A. Cole
Connor McGuckin
Chunyan Ren
Jing Zeng
Mir Hossain
Kevin Luk
Scot A. Wolfe
Luca Pinello
Daniel E. Bauer
机构
[1] Harvard Medical School,Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana
[2] Harvard Medical School,Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Department of Pediatrics
[3] University of Massachusetts Medical School,Molecular Pathology Unit, Center for Cancer Research, Massachusetts General Hospital, Department of Pathology
来源
Nature Genetics | 2021年 / 53卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Known fetal hemoglobin (HbF) silencers have potential on-target liabilities for rational β-hemoglobinopathy therapeutic inhibition. Here, through transcription factor (TF) CRISPR screening, we identify zinc-finger protein (ZNF) 410 as an HbF repressor. ZNF410 does not bind directly to the genes encoding γ-globins, but rather its chromatin occupancy is concentrated solely at CHD4, encoding the NuRD nucleosome remodeler, which is itself required for HbF repression. CHD4 has two ZNF410-bound regulatory elements with 27 combined ZNF410 binding motifs constituting unparalleled genomic clusters. These elements completely account for the effects of ZNF410 on fetal globin repression. Knockout of ZNF410 or its mouse homolog Zfp410 reduces CHD4 levels by 60%, enough to substantially de-repress HbF while eluding cellular or organismal toxicity. These studies suggest a potential target for HbF induction for β-hemoglobin disorders with a wide therapeutic index. More broadly, ZNF410 represents a special class of gene regulator, a conserved TF with singular devotion to regulation of a chromatin subcomplex.
引用
收藏
页码:719 / 728
页数:9
相关论文
共 97 条
  • [1] Orkin SH(2019)Emerging genetic therapy for sickle cell disease Annu. Rev. Med. 70 257-271
  • [2] Bauer DE(2017)Sickle cell disease N. Engl. J. Med. 377 302–305-175
  • [3] Piel FB(2018)The evolving spectrum of the epidemiology of thalassemia Hematol. Oncol. Clin. North Am. 32 165-1842
  • [4] Steinberg MH(2008)Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A Science 322 1839-289
  • [5] Rees DC(2016)Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin Science 351 285-1159
  • [6] Weatherall DJ(2019)Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis Nat. Genet. 51 1149-3501
  • [7] Sankaran VG(2013)Mi2β-mediated silencing of the fetal γ-globin gene in adult erythroid cells Blood 121 3493-503
  • [8] Masuda T(2018)Natural regulatory mutations elevate fetal globin via disruption of BCL11A or ZBTB7A binding Nat. Genet. 50 498-442
  • [9] Sher F(2018)Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch Cell 173 430-6523
  • [10] Amaya M(2013)Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A Proc. Natl Acad. Sci. USA 110 6518-540